Anne Floyd, MD
Ophthalmology · Glendale, AZNPI 1023454410
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 279 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Among ophthalmology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $38.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Glaukos Corporation$1K
- AbbVie$1K
- Bausch & Lomb Americas Inc.$912
- Bausch & Lomb, A Division Of Bausch Health US, LLC$881
- Johnson & Johnson Surgical Vision, Inc.$725
- plus $4K from 24 others
What the payments were for
- Food & beverage$10,65199%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 24 | $1,677 |
| Glaukos Corporation | 17 | $1,475 |
| AbbVie(2 entities) | 55 | $1,333 |
| Bausch & Lomb Americas Inc. | 26 | $912 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 27 | $881 |
| Johnson & Johnson Surgical Vision, Inc. | 15 | $725 |
| Aerie Pharmaceuticals, Inc. | 10 | $403 |
| Sight Sciences, Inc. | 6 | $400 |
| Amgen(2 entities) | 13 | $348 |
| Sun Pharmaceutical Industries Inc. | 18 | $320 |
| Novartis | 18 | $307 |
| Dompe US, Inc. | 5 | $283 |
| Mallinckrodt Enterprises LLC | 7 | $244 |
| Kala Pharmaceuticals, Inc. | 8 | $244 |
| Harrow Eye, LLC | 2 | $188 |
| Rxsight Inc | 3 | $150 |
| Nova Eye, Inc. | 1 | $133 |
| Ivantis, Inc | 1 | $116 |
| Mallinckrodt Hospital Products Inc. | 4 | $102 |
| Tarsus Pharmaceuticals, Inc. | 3 | $83 |
| Genentech USA, Inc. | 1 | $81 |
| Oyster Point Pharma, Inc. | 3 | $69 |
| Rayner Intraocular Lenses Limited | 2 | $60 |
| Biotissue Holdings Inc. | 2 | $46 |
| Shire North American Group Inc | 2 | $39 |
| Akorn Operating Company LLC | 2 | $37 |
| Astellas Pharma US Inc | 1 | $21 |
| Travere Therapeutics, Inc. | 1 | $19 |
| Thea Pharma Inc. | 1 | $18 |
| Ocular Therapeutix, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$665
- Tecnis IOL$492
- Tecnis Simplicity$477
- iDoseTR$398
- iStent inject W$326
- STELLARIS$278
- OMNI(R) SURGICAL SYSTEM (US)$232
- DURYSTA$217
- LOTEMAX SM$211
- VYZULTA$200
- Flarex$173
- IHEEZO$173
- Verkazia$173
- Tobradex ST$173
- Natacyn$173
- iStent inject Trabecular Micro-Bypass Stent System$148
- iStent Infinite$138
- VERITAS Vision System$127
- ACTHAR$125
- TEPEZZA$125
How this compares
$10,731 in reported general payments places this provider in the 90th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 53 | $18,115 |
| RestasisCyclosporine | 12 | $8,606 |
| Prednisolone Acetate | 78 | $3,306 |
| Travoprost | 15 | $2,157 |
| Latanoprost | 181 | $1,771 |
| MoxifloxacinMoxifloxacin Hcl | 26 | $880 |
| Ketorolac Tromethamine | 13 | $622 |
| Dorzolamide Hcl | 20 | $490 |
| Timolol Maleate | 58 | $487 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 16 | $242 |
| Brimonidine Tartrate | 15 | $178 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 15 | $175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis | $1,333 | $26,72165 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Glendale
- Shamil PatelGlendale$116K
- George ReissGlendale$73K
- Wendy HuangGlendale$73K
- Warren HillMesa$1.1M
- Mark BarakatScottsdale$794K
- Anne ZakiSun City West$518K
- Pravin DugelPhoenix$176K
- Derek KunimotoMesa$138K
- Yuri McKeeMesa$100K
- Nishi ShahPhoenix$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.